Skip to main
  1. Stocks
  2. RxSight
  3. Forecast
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 13%
Buy 0%
Hold 75%
Sell 13%
Strong Sell 0%

Bulls say

RxSight is supported by a differentiated light adjustable lens platform that continues to show pockets of strength through higher physician engagement and practice integration, while the Alcon collaboration underscores the value of its technology and could add $60M upfront plus up to $140M in milestones and royalties. Despite 3Q26 revenue missing consensus because of competitive pressures and restructuring-related disruption, gross margin remained strong at 73.6% and beat expectations, while operating expenses were about flat year over year at $36.6M, suggesting improving operating leverage. The investment case is strengthened by management’s shift toward increasing utilization across the installed base, more selective LDD placements, and a restructuring that is expected to lower 2027 opex, all of which support a path back to growth and improved cash burn.

Bears say

RxSight is facing deteriorating fundamentals as 3Q26 revenue fell 19% year over year to $24.6M, missing consensus on weaker LAL and LDD volumes, while adjusted EPS of -$0.21 and 73.6% gross margin showed both operating losses and margin compression from higher inventory costs and reserves. Competitive pressures, including trialing from a rival launch, and disruption from sales force reorganization have reduced utilization to 6.6 LALs per LDD, while the company also posted steep declines in LDD placements and warned that new LDD sales may remain nominal. The absence of FY guidance after withdrawal, elevated operating expenses of $36.6M, and uncertainty around execution during leadership and commercial strategy changes support a cautious outlook despite cash and restructuring efforts.

RxSight (RXST) has been analyzed by 8 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

RxSight (RXST) Analyst Forecast & Price Prediction

Get the latest RxSight (RXST) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RxSight (RXST)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 8 analysts, RxSight (RXST) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


RxSight (RXST) Analyst Forecast & Price Prediction

Get the latest RxSight (RXST) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RxSight (RXST)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RXST stock data and trends